Pidnarulex is under clinical development by Senhwa Biosciences and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Pidnarulex’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Pidnarulex is under development for the treatment of relapsed/refractory haematological malignancies including non-Hodgkin lymphoma, acute myeloid leukemia, multiple myeloma, triple negative breast cancer, advanced castration-resistant prostate cancer, chemotherapy resistant epithelial ovarian cancer, pancreatic cancer, ovarian cancer, peritoneal cancer, fallopian tube cancer, prostate cancer, breast cancer, pediatric neuroblastoma and other cancers. It is administered through intravenous route. The drug candidate targets RNA polymerase I and topoisomerase II beta. It is a G4-stabilizing compound. The drug candidate is developed based on synthetic lethality technology.
Senhwa Biosciences overview
Senhwa Biosciences (Senhwa) is a clinical-stage drug development company. The company develops next-generation DNA damage response drugs for the treatment of cancer. Its pipeline products include CX-5461 and CX-4945. Its CX-5461 product is used for the treatment of breast cancer, ovarian cancer or solid tumors and hematological malignancies. The company’s other product candidate CX-4945 is used for the treatment of prostate cancer, cholangiocarcinoma, basal cell carcinoma, medulloblastoma and COVID-19. It collaborates with global investigators and service providers to develop its pipeline products. The company has operations in Taiwan and the US. Senhwa is headquartered in New Taipei City, Taipei, Taiwan.
For a complete picture of Pidnarulex’s drug-specific PTSR and LoA scores, buy the report here.